Alexander A. Pieper

Alexander A. Pieper

Auto-generated profile, based on publicly available information

Alexander A. Pieper

Department of Radiology, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, Wisconsin

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2021 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
APAlexander A Pieper
Alexander A Pieper
ARAlexander L Rakhmilevich
Alexander L Rakhmilevich
DSDaniel V Spiegelman
Daniel V Spiegelman
RPRavi Patel
Ravi Patel
JBJen Birstler
Jen Birstler
PSPaul Sondel
Paul Sondel
Background: Current clinical trials are using radiation therapy (RT) to enhance an antitumor response elicited by high-dose interleukin (IL)-2 therapy or immune checkpoint blockade (ICB). Bempegaldesleukin (BEMPEG) is an investigational CD122-preferential IL-2 pathway agonist with prolonged in vivo half-life and preferential intratumoral expansion of T effector cells over T regulatory cells. BEMPEG has shown encouraging safety and efficacy in clinical trials when used in combination with PD-1 checkpoint blockade. In this study, we investigated the antitumor effect of local RT combined with BEMPEG in multiple immunologically ‘cold’ tumor models. Additionally, we asked if ICB could further enhance the local and distant antitumor effect of RT+BEMPEG in the setting of advanced solid tumors or metastatic disease. Methods: Mice bearing flank tumors (B78 melanoma, 4T1 breast cancer, or MOC2 head and neck squamous cell carcinoma) were treated with combinations of RT and immunotherapy (including BEMPEG, high-dose IL-2, anti(α)-CTLA-4, and α-PD-L1). Mice bearing B78 flank tumors were injected intravenously with B16 melanoma cells to mimic metastatic disease and were subsequently treated with RT and/or immunotherapy. Tumor growth and survival were monitored. Peripheral T cells and tumor-infiltrating lymphocytes were assessed via flow cytometry. Results: A cooperative antitumor effect was observed in all models when RT was combined with BEMPEG, and RT increased IL-2 receptor expression on peripheral T cells. This cooperative interaction was associated with increased IL-2 receptor expression on peripheral T cells following RT. In the B78 melanoma model, RT+BEMPEG resulted in complete tumor regression in the majority of mice with a single ~400 mm3 tumor. This antitumor response was T-cell dependent and supported by long-lasting immune memory. Adding ICB to RT+BEMPEG strengthened the antitumor response and cured the majority of mice with a single ~1000 mm3 B78 tumor. In models with disseminated metastasis (B78 primary with B16 metastasis, 4T1, and MOC2), the triple combination of RT, BEMPEG, and ICB significantly improved primary tumor response and survival. Conclusion: The combination of local RT, BEMPEG, and ICB cured mice with advanced, immunologically cold tumors and distant metastasis in a T cell-dependent manner, suggesting this triple combination warrants clinical testing.

15 August 2022 in IEEE Transactions on Biomedical Engineering
Verified
Journal Article
Closed access
MWMartin G. Wagner
Martin G. Wagner
SPSarvesh Periyasamy
Sarvesh Periyasamy
AKAyca Z. Kutlu
Ayca Z. Kutlu
APAlexander A. Pieper
Alexander A. Pieper
JSJohn F. Swietlik
John F. Swietlik
PLPaul F. Laeseke
Paul F. Laeseke
Objective: Histotripsy is an emerging noninvasive, nonionizing and nonthermal focal cancer therapy that is highly precise and can create a treatment zone of virtually any size and shape. Current histotripsy systems rely on ultrasound imaging to target lesions. However, deep or isoechoic targets obstructed by bowel gas or bone can often not be treated safely using ultrasound imaging alone. This work presents an alternative x-ray C-arm based targeting approach and a fully automated robotic targeting system. Methods: The approach uses conventional cone beam CT (CBCT) images to localize the target lesion and 2D fluoroscopy to determine the 3D position and orientation of the histotripsy transducer relative to the C-arm. The proposed pose estimation uses a digital model and deep learning-based feature segmentation to estimate the transducer focal point relative to the CBCT coordinate system. Additionally, the integrated robotic arm was calibrated to the C-arm by estimating the transducer pose for four preprogrammed transducer orientations and positions. The calibrated system can then automatically position the transducer such that the focal point aligns with any target selected in a CBCT image. Results: The accuracy of the proposed targeting approach was evaluated in phantom studies, where the selected target location was compared to the center of the spherical ablation zones in post-treatment CBCTs. The mean and standard deviation of the Euclidean distance was $\mathbf {1.4 \pm 0.5}$ mm. The mean absolute error of the predicted treatment radius was $\mathbf {0.5 \pm 0.5}$ mm. Conclusion: CBCT-based histotripsy targeting enables accurate and fully automated treatment without ultrasound guidance. Significance: The proposed approach could considerably decrease operator dependency and enable treatment of tumors not visible under ultrasound.

13 January 2023 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
PCPeter M Carlson
Peter M Carlson
RPRavi Patel
Ravi Patel
JBJen Birstler
Jen Birstler
MRMatthew Rodriquez
Matthew Rodriquez
CSClaire Sun
Claire Sun
ZMZachary S. Morris
Zachary S. Morris
Background: The antitumor effects of external beam radiation therapy (EBRT) are mediated, in part, by an immune response. We have reported that a single fraction of 12 Gy EBRT combined with intratumoral anti-GD2 hu14.18-IL2 immunocytokine (IC) generates an effective in situ vaccine (ISV) against GD2-positive murine tumors. This ISV is effective in eradicating single tumors with sustained immune memory; however, it does not generate an adequate abscopal response against macroscopic distant tumors. Given the immune-stimulatory capacity of radiation therapy (RT), we hypothesized that delivering RT to all sites of disease would augment systemic antitumor responses to ISV. Methods: We used a syngeneic B78 murine melanoma model consisting of a ‘primary’ flank tumor and a contralateral smaller ‘secondary’ flank tumor, treated with 12 Gy EBRT and intratumoral IC immunotherapy to the primary and additional EBRT to the secondary tumor. As a means of delivering RT to all sites of disease, both known and occult, we also used a novel alkylphosphocholine analog, NM600, conjugated to 90Y as a targeted radionuclide therapy (TRT). Tumor growth, overall survival, and cause of death were measured. Flow cytometry was used to evaluate immune population changes in both tumors. Results: Abscopal effects of local ISV were amplified by delivering as little as 2–6 Gy of EBRT to the secondary tumor. When the primary tumor ISV regimen was delivered in mice receiving 12 Gy EBRT to the secondary tumor, we observed improved overall survival and more disease-free mice with immune memory compared with either ISV or 12 Gy EBRT alone. Similarly, TRT combined with ISV resulted in improved overall survival and a trend towards reduced tumor growth rates when compared with either treatment alone. Using flow cytometry, we identified an influx of CD8+ T cells with a less exhausted phenotype in both the ISV-targeted primary and the distant secondary tumor following the combination of secondary tumor EBRT or TRT with primary tumor ISV. Conclusions: We report a novel use for low-dose RT, not as a direct antitumor modality but as an immunomodulator capable of driving and expanding antitumor immunity against metastatic tumor sites following ISV.

5 April 2023 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
APAlexander A. Pieper
Alexander A. Pieper
DSDan V. Spiegelman
Dan V. Spiegelman
MFMildred A. R. Felder
Mildred A. R. Felder
AFArika S. Feils
Arika S. Feils
NTNoah W. Tsarovsky
Noah W. Tsarovsky
PSPaul Sondel
Paul Sondel
Background: The in-situ vaccine using CpG oligodeoxynucleotide combined with OX40 agonist antibody (CpG + OX40) has been shown to be an effective therapy activating an anti-tumor T cell response in certain settings. The roles of tumor volume, tumor model, and the addition of checkpoint blockade in the efficacy of CpG + OX40 in-situ vaccination remains unknown. Methods: Mice bearing flank tumors (B78 melanoma or A20 lymphoma) were treated with combinations of CpG, OX40, and anti-CTLA-4. Tumor growth and survival were monitored. In vivo T cell depletion, tumor cell phenotype, and tumor infiltrating lymphocyte (TIL) studies were performed. Tumor cell sensitivity to CpG and macrophages were evaluated in vitro. Results: As tumor volumes increased in the B78 (one-tumor) and A20 (one-tumor or two-tumor) models, the anti-tumor efficacy of the in-situ vaccine decreased. In vitro, CpG had a direct effect on A20 proliferation and phenotype and an indirect effect on B78 proliferation via macrophage activation. As A20 tumors progressed in vivo, tumor cell phenotype changed, and T cells became more involved in the local CpG + OX40 mediated anti-tumor response. In mice with larger tumors that were poorly responsive to CpG + OX40, the addition of anti-CTLA-4 enhanced the anti-tumor efficacy in the A20 but not B78 models. Conclusions: Increased tumor volume negatively impacts the anti-tumor capability of CpG + OX40 in-situ vaccine. The addition of checkpoint blockade augmented the efficacy of CpG + OX40 in the A20 but not B78 model. These results highlight the importance of considering multiple preclinical model conditions when assessing the efficacy of cancer immunotherapy regimens and their translation to clinical testing.

19 June 2024 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
SPSarvesh Periyasamy
Sarvesh Periyasamy
EOErick L. Oberstar
Erick L. Oberstar
JWJoseph F. Whitehead
Joseph F. Whitehead
AKAyca Z. Kutlu
Ayca Z. Kutlu
APAlexander A. Pieper
Alexander A. Pieper
PLPaul F. Laeseke
Paul F. Laeseke

18 March 2024 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
APAlexander A. Pieper
Alexander A. Pieper
NSNicholas A. Stowe
Nicholas A. Stowe
SPSarvesh Periyasamy
Sarvesh Periyasamy
BBBrian M. Burkel
Brian M. Burkel
NTNoah W. Tsarovsky
Noah W. Tsarovsky
JJJohn-Paul J.
John-Paul J.